Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
企業コードMYNZ
会社名Mainz Biomed NV
上場日Nov 04, 2021
最高経営責任者「CEO」Mr. Guido Baechler
従業員数19
証券種類Ordinary Share
決算期末Nov 04
本社所在地Sirius Gutenberg Park
都市MAINZ
証券取引所NASDAQ Capital Market Consolidated
国Germany
郵便番号55129
電話番号4961315542860
ウェブサイトhttps://www.mainzbiomed.com/
企業コードMYNZ
上場日Nov 04, 2021
最高経営責任者「CEO」Mr. Guido Baechler
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし